Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

13P - Universal prospects of cryopreserved umbilical cord blood CD34+ progenitor cell-derived NK cells: Clinical and preclinical evaluation of non-engineered and genetically engineered candidates


06 Mar 2023


Cocktail & Poster Display session


Anna-Maria Georgoudaki


Annals of Oncology (2023) 8 (1suppl_2): 100900-100900. 10.1016/esmoop/esmoop100900


A. Georgoudaki, N. Lamers-Kok, A. Van Vliet, D. Özkazanc, D. Vodegel, D. Steenmans, M. Raimo, A.D. Duru, J. Spanholtz

Author affiliations

  • Research Department, Glycostem Therapeutics, 5349 AB - Oss/NL


This content is available to ESMO members and event participants.

Abstract 13P


Natural killer cells (NK) are gaining traction as (non-)engineered cell therapy products also used in combination therapies. Glycostem’s ex vivo expansion and differentiation method in a fully closed automated manufacturing platform (uNiKTM), generates GTA002 (oNKord®), an “off-the-shelf” allogeneic cryopreserved NK cell product from umbilical cord blood-derived CD34+ progenitors. Safety and tolerability of a fresh predecessor was shown in a phase I trial in AML and a phase II trial of oNKord® in AML is now on-going. Recent preclinical assessments elucidate the capacity of GTA002 to target hematological and solid malignancies.


Potency assays in combination with receptor blocking monoclonal antibodies (mAb) for assessment of cytotoxicity and receptor involvement were performed in 2D by flow cytometry and in 3D spheroids by Incucyte. GTA002’s capacity to upregulate CD16a in vivo spurred the exploration of antibody-dependent cellular cytotoxicity ADCC against otherwise non-susceptible targets.


GTA002 showed rapid cytotoxic responses against melanoma cell lines at low effector:target ratios. The involvement of several activating receptors, and specifically death receptor TRAIL, for efficient cytotoxicity was revealed. Multimodal activation for efficient cytotoxicity was verified in both 2D and 3D melanoma models. Pre-clinical results show rapid ADCC against HER2+ and CD19+ tumors within a few hours from target exposure to GTA002. Furthermore, approaches to genetically equip GTA002 with chimeric antigen receptors to generate viveNKTM cells, recently showed efficient preclinical antigen-specific targeting of HER2+ and CD19+ tumors, while preserving innate NK cell cytotoxicity.


Overall, the preclinical innate performance and ADCC of cryopreserved “off-the-shelf” oNKord® cells as well as the cytotoxicity of viveNKTM cells demonstrate the great potential of multimodal targeting against a variety of cancer indications, and open up opportunities for combination therapies with a vast array of established mAb therapeutics and bispecific NK cell engagers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Glycostem Therapeutics.


A. Georgoudaki, N. Lamers-Kok, A. Van Vliet, D. Özkazanc, D. Vodegel, D. Steenmans, M. Raimo, A.D. Duru, J. Spanholtz: Financial Interests, Personal, Full or part-time Employment: Glycostem Therapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.